Wegovy Heart Side Effects: What the Evidence Actually Shows

Step 1: What happens to your heart rate when you start Wegovy

A rise in resting heart rate is one of the most consistently reported cardiovascular findings with GLP-1 receptor agonists, including semaglutide. In clinical trials, the average increase was small, typically around one to four beats per minute above baseline, and it tended to be most noticeable in the first few weeks as the body adjusts to treatment. For the majority of people this goes unnoticed entirely.

If you wear a fitness tracker, you may spot it before you feel it. That is not a cause for alarm on its own. A small number of people notice a fluttery or racing sensation, particularly after moving from sitting to standing quickly, in the early weeks. This often settles once the dose has been at the same level for a month or so. Our detailed page on Wegovy's effect on heart rate covers the mechanics in more depth if you want specifics.

What you should not do is try to manage a persistent or worsening fast heartbeat by simply adjusting your own dose or stopping suddenly. Both decisions carry their own risks and belong with your prescriber. Noting the pattern, including when it happens and for how long, and reporting it at your next clinical review is the right first step for a mild, occasional increase.

The NHS medicines page for semaglutide lists increased heart rate as a known side effect and advises telling your doctor if it becomes troublesome.

Step 2: Understanding the cardiovascular benefit side of the picture

It is easy to read "heart side effects" and assume the news is all bad. The fuller picture is more interesting. The SELECT trial, a large randomised study of adults with obesity and established cardiovascular disease (but without diabetes), found that weekly semaglutide 2.4 mg cut the rate of major cardiovascular events, including heart attack and stroke, by around 20% compared with placebo over roughly three years.

This is why the broader conversation about semaglutide and heart health is genuinely nuanced. The medicine carries both a small upward nudge to resting pulse and, in people with pre-existing heart disease, a meaningful reduction in serious outcomes. Those two facts coexist.

It is also why eligibility matters so much. The cardiovascular benefit applies to a specific group: adults with existing cardiovascular disease and a BMI of 30 or above. It does not automatically translate to everyone who takes Wegovy. Your prescriber's job, before any script is written, is to look at your particular history and decide whether the balance of benefit and risk makes sense for you. Semaglutide has also received UK authorisation for reducing cardiovascular event risk in eligible adults as a formal indication, separate from weight management alone.

If you are exploring treatment options more broadly, the Wegovy overview page covers licensing and eligibility in plain language.

Step 3: Recognising symptoms that need prompt medical attention

Most heart-related sensations people notice on Wegovy are minor and self-limiting. Some are not, and the distinction is important.

Seek same-day medical assessment, or call 999 if severe, for: chest pain or tightness, breathlessness at rest or when doing very little, a heartbeat that feels irregular or extremely fast and does not calm down within a few minutes, fainting or near-fainting, or swelling in your legs that develops suddenly. These symptoms are not typical Wegovy side effects; they are signals that something unrelated, or a rare adverse reaction, may need urgent evaluation.

The MHRA Yellow Card scheme lets patients report unexpected side effects directly, and doing so contributes to ongoing safety monitoring for medicines like Wegovy. It is a straightforward online form and takes around ten minutes.

For the broader set of gastrointestinal and other Wegovy effects, the full side effects guide covers what is common, what is rare, and what the clinical evidence says about how long each tends to last.

Step 4: What to raise at your clinical review

This is where everything comes together practically. Before treatment starts, a prescriber needs to know about any existing heart conditions, arrhythmias, pacemakers, relevant family history, and any medicines you already take that affect heart rate or blood pressure. That conversation is not a formality. It is the mechanism that makes prescribing safe.

During treatment, the question to bring to each review is straightforward: has anything changed? If your resting pulse has climbed significantly, if you have noticed palpitations on most days, or if a new symptom has appeared, say so. Prescribers can adjust the titration pace, check whether another medicine might be interacting, or refer for further assessment if warranted.

Some people find the side-effect picture is lighter than they expected. If you are curious about why that varies between individuals, the page on experiencing no side effects on Wegovy explores the reasons. And for anyone thinking about what heartburn and reflux on Wegovy feel like compared with cardiac discomfort, our Wegovy and heartburn page explains the difference.

At nume, every repeat prescription is reviewed by a real clinician before it is issued. If you are thinking about starting treatment or want to understand how your cardiovascular history fits the eligibility picture, checking your eligibility through a free consultation is the natural first step. There is no obligation and the assessment is thorough.